CD70-targeting chimeric antigen receptor

CD70-targeting chimeric antigen receptor (CAR) therapies represent a class of cell-based immunotherapies engineered to target CD70 (also known as CD27L), a member of the tumor necrosis factor (TNF) superfamily. CD70 is aberrantly and constitutively expressed in a wide range of malignancies, including hematological cancers such as acute myeloid leukemia (AML), non-Hodgkin lymphoma, and multiple myeloma, as well as solid tumors like clear cell renal cell carcinoma (RCC) and glioblastoma. These therapies typically utilize autologous or allogeneic T cells (CAR-T) or NK cells (CAR-NK) modified with a synthetic receptor comprising an extracellular CD70-binding domain (often derived from the natural ligand CD27 or a humanized scFv), a transmembrane domain, and intracellular signaling domains such as CD3-zeta and co-stimulatory domains (e.g., 4-1BB or CD28). The binding of the CAR to CD70 on tumor cells triggers immune cell activation and targeted cytolysis. As of 2024–2025, numerous candidates are in clinical development, including programs from Allogene Therapeutics, CRISPR Therapeutics, and BioCell Innovations.

Other names

CD70 CAR-TCD-70 CAR-TCD 70 CAR-TCD70 CAR-NKCD-70 CAR-NKCD 70 CAR-NKCD70 CAR-NKTCD-70 CAR-NKTCD 70 CAR-NKTCD70-directed CARCD-70-directed CARCD 70-directed CARanti-CD70 CARanti-CD-70 CARanti-CD 70 CAR